New anti-CD47 mAb!

CD47 is emerging as a promising intervention point in Cancer therapy.

Head and Neck Squamous Cell Carcinoma: 

Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.  Wu L, Sun ZJ, et al. (2018) Oncoimmunology 7(4): e1397248. Doi: 10.1080/2162402X.2017.1397248.

Glioma: 

Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells    Lif F, Jiang X, et al. (2017) Oncoimmunology 7(2): e1391973. doi: 10.1080/2162402X.2017.1391973.

Breast Cancer:

CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT Norman MZ, Janji B, et al. (2018) Oncoimmunology. 7(4):e1345415. doi: 10.1080/2162402X.2017.1345415.

Relevant Ancell Products:

anti-CD47 mAb and conjugates